All patients with SMAD7 T/N ratios <1 showed strong pSMAD2 positivity in the tumors, suggesting enhanced TGF-β signaling in tumors with low SMAD7 levels, while STAT3 signaling was only activated in three patients and not all tumor cells. This evidence concerns the gene SMAD7 and neoplasm.